Page 7 - அகஸ்டா பல்கலைக்கழகம் மருத்துவ கல்லூரி ஆஃப் ஜார்ஜியா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from அகஸ்டா பல்கலைக்கழகம் மருத்துவ கல்லூரி ஆஃப் ஜார்ஜியா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In அகஸ்டா பல்கலைக்கழகம் மருத்துவ கல்லூரி ஆஃப் ஜார்ஜியா Today - Breaking & Trending Today

ASCO GU 2021: Clinical Outcomes of Patients With mCRPC Receiving Radium-223 Early Versus Late in the Treatment Sequence

SHARE
ASCO GU 2021: Clinical Outcomes of Patients With mCRPC Receiving Radium-223 Early Versus Late in the Treatment Sequence
Published 11 February 2021
(UroToday.com) Data from the landmark ALSYMPCA trial
1 found that the targeted alpha therapy Radium-223 prolonged overall survival in men with metastatic castration-resistant prostate cancer (mCRPC).
1 However, there is little data to guide clinicians as to the appropriate sequence for use of Radium-223 in men with mCRPC with regards to other life-prolonging therapies. At the 2021 ASCO Genitourinary Cancers Symposium (ASCO GU), Dr. Lawrence Mbuagbaw and colleagues presented results of their real-world study evaluating clinical outcomes of patients when Radium-223 was used early (second-line) or late (third or later lines) among men with mCRPC. ....

United States , Zachary Klaassen , Lawrence Mbuagbaw , Richardm Lee Ying , Jennifer Lowther , Mcmaster University , Ontario Institute For Clinical Evaluative Sciences , Augusta University Medical College Of Georgia , Bayer Inc , University Of Calgary , Georgia Cancer Center , Tom Baker Cancer Center , Cancers Symposium , Clinical Evaluative Sciences , Charlson Comorbidity Index , Urologic Oncologist , Assistant Professor , Medical College , ஒன்றுபட்டது மாநிலங்களில் , சக்கரி க்லாஸ்சேங் , ஜெனிபர் தாழ்வான , மக்மாஸ்டர் பல்கலைக்கழகம் , அகஸ்டா பல்கலைக்கழகம் மருத்துவ கல்லூரி ஆஃப் ஜார்ஜியா , பேயர் இன்க் , பல்கலைக்கழகம் ஆஃப் கல்கரி , ஜார்ஜியா புற்றுநோய் மையம் ,

ASCO GU 2021: Radical Cystectomy for High-Risk Non-Muscle-Invasive Bladder Cancer: Who and Why?

Published 16 February 2021
(UroToday.com) The optimizing personalized management of non-muscle-invasive bladder cancer session at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) included a presentation from Dr. Anne Schuckman discussing which patients with high-risk non-muscle-invasive bladder cancer may benefit from radical cystectomy. Dr. Shuckman notes that more than 70% of all newly diagnosed bladder cancers are non-muscle-invasive, including Ta (70%), T1 (20%), and CIS (10%). The natural history of non-muscle-invasive bladder cancer stratified by low-grade Ta, high-grade Ta and high-grade T1 is depicted in the following table:
Data from Moschini and colleagues suggest that whether T2 disease is de novo or progressive is prognostically important. ....

United States , Zachary Klaassen , Anne Schuckman , Los Angeles , Annek Schuckman , Georgia Cancer Center , Augusta University Medical College Of Georgia , Clinical Oncology Genitourinary Cancers Symposium , Assistant Professor , Keck Hospital , Cancer Hospital , Urologic Oncologist , Medical College , ஒன்றுபட்டது மாநிலங்களில் , சக்கரி க்லாஸ்சேங் , லாஸ் ஏஞ்சல்ஸ் , ஜார்ஜியா புற்றுநோய் மையம் , அகஸ்டா பல்கலைக்கழகம் மருத்துவ கல்லூரி ஆஃப் ஜார்ஜியா , உதவியாளர் ப்ரொஃபெஸர் , கேக்க் மருத்துவமனை , புற்றுநோய் மருத்துவமனை , சிறுநீரக புற்றுநோயியல் நிபுணர் , மருத்துவ கல்லூரி ,

ASCO GU 2021: Deintensification of Management of Low-Risk Non-Muscle-Invasive Bladder Cancer

Published 16 February 2021
(UroToday.com) The optimizing personalized management of non-muscle-invasive bladder cancer session at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) included a presentation from Dr. Angela Smith discussing deintensification of management of low-risk non-muscle-invasive bladder cancer. Dr. Smith notes that it is important to distinguish between low risk versus low grade non-muscle-invasive bladder cancer. According to the AUA risk stratification for non-muscle-invasive bladder cancer low risk disease is either a low-grade solitary Ta 3 cm tumor or PUNLMP. Conversely, there are several instances where low grade tumors are intermediate risk, including low grade Ta tumors that recur within 1 year of resection, solitary low grade Ta tumors 3cm, and multifocal low grade Ta tumors. ....

United States , Chapel Hill , Zachary Klaassen , Androl Urol , Angelab Smith , Angela Smith , Academic Affairs , Georgia Cancer Center , Augusta University Medical College Of Georgia , University Of North Carolina , Clinical Oncology Genitourinary Cancers Symposium , Bladder Cancer Monitor , Bladder Epicheck , Expert Opinion , Vice Chair Of Academic Affairs , Director Of Urologic Oncology , Associate Professor Of Urology , North Carolina , Urologic Oncologist , Assistant Professor , Medical College , Eur Urol , Transl Androl , ஒன்றுபட்டது மாநிலங்களில் , தேவாலயம் மலை , சக்கரி க்லாஸ்சேங் ,

ASCO GU 2021: Best of Journals: Renal Cell Carcinoma – Medical Oncology

Published 14 February 2021
(UroToday.com) The 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium included a Best of Journals: Renal Cell Carcinoma Session with Dr. Saby George from the Roswell Park Cancer Institute presenting impactful papers from the medical oncology perspective.
The first paper discussed by Dr. George was Motzer et al. s “Nivolumab Versus Everolimus in Patients with Advanced Renal Cell Carcinoma: Updated Results with Long-Term Follow-Up of the Randomized, Open-Label, Phase 3 CheckMate 025 Trial” was published in
Cancer.
1 CheckMate 025 previously showed superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma along with improved safety and tolerability. ....

New York , United States , Roswell Park , Habib Hamidi , Zachary Klaassen , David Mcdermott , Saby George , Scotts Tykodi , Bernard Escudier , Jeffreya Sosman , Romain Banchereau , Thomas Powles , Michaelb Atkins , American Society Of Clinical Oncology , Georgia Cancer Center , Roswell Park Cancer Institute , Augusta University Medical College Of Georgia , Clinical Oncology , Cancers Symposium , Renal Cell Carcinoma Session , Versus Everolimus , Advanced Renal Cell Carcinoma , Updated Results , Long Term Follow Up , Renal Cancer Determine Outcome , Associate Professor ,

ASCO GU 2021: Characterization of FOXF1 as a Novel Regulator of Nodal Metastasis in Bladder Cancer

Published 14 February 2021
(UroToday.com) Members of the forkhead transcription factor (FOX) family are important mediators of embryonic development and are known to be altered in a variety of cancers. However, to date, the functional role of
FOXF1 in bladder tumorigenesis and progression has not been clearly characterized. At the 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Dr. Anirban Mitra and colleagues from the MD Anderson Cancer Center reported results of their study investigating the clinical implications of differential
FOXF1 expression in bladder cancer, and potential mechanisms by which its alteration can lead to tumor metastasis.
For this study, whole-genome expression profiling was performed on paired primary tumors and nodal metastases from a radical cystectomy discovery cohort using Illumina HT12 v3-4 BeadChip arrays to identify ....

United States , Zachary Klaassen , Anirban Mitra , Anirbanp Mitra , American Society Of Clinical Oncology , University Of Texas Md Anderson Cancer Center , Georgia Cancer Center , Augusta University Medical College Of Georgia , Md Anderson Cancer Center , Clinical Oncology , Cancers Symposium , Cancer Center , Urologic Oncology , Urologic Oncologist , Assistant Professor , Medical College , Clinical Oncology Genitourinary Cancers Symposium , ஒன்றுபட்டது மாநிலங்களில் , சக்கரி க்லாஸ்சேங் , அனிர்பன் மித்ரா , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் , ஜார்ஜியா புற்றுநோய் மையம் , அகஸ்டா பல்கலைக்கழகம் மருத்துவ கல்லூரி ஆஃப் ஜார்ஜியா , ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் , மருத்துவ புற்றுநோயியல் ,